Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors.
We have generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells.
Our SPEAR T-cell therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. Adaptimmune partners with industry leaders in all areas of its business.